Business Wire

Kasturba Medical College, India Wins XV Fujio Cup Quiz in NCRM NICHE 2020

19.10.2020 10:55:00 EEST | Business Wire | Press release

Share

Sufyan Ibrahim and Himanshu Yashavanthi Nagesh of Kasturba Medical College, India, won the prestigious Fujio Cup Quiz (FCQ), an active knowledge gaining academic event of NCRM NICHE 2020, on stem cells and regenerative medicine, in a toughly fought contest among teams representing Monash University, Australia, Birla Institute of Technology (BITS-Pilani), India and Bandung Institute of Technology, Indonesia, who came second. The virtual event had lectures by Prof. Masaharu Seno, Okayama University on induced pluripotent stem cells, Dr Maria Nostro, University of Toronto on pancreatic progenitors for diabetes and Fr Francis Xavier, Loyola College, Chennai in the inter-disciplinary conclave on stress management during Covid-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005298/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Winners of XV Fujio Cup Quiz, Dr. Ibrahim and Mr. Nagesh of Kasturba Medical College, India, with the 2020- Joyce and James Till Travel Grant Awardee, Dr. Natarajan, a 2013- FCQ Elite. (Graphic: Business Wire)

Regenerative Medicine is a specialty demanding inter-disciplinary interaction, as physical forces like gravity and elasticity, chemically synthesized polymers and nanomaterial scaffolds, provide suitable micro environment to the cells for in vitro culture in the lab, which are transplanted to replace, restore, repair and regenerate tissues to address organ failures. FCQ, a part of NCRM NICHE started in 2006 is conducted in Tokyo, Japan, since 2017 in which young scholars of different specialties of science from all over the world participate, cross several steps of quizzing and assignments to win the trophy. Alumni of top scoring teams of FCQ (FCQ elites) are eligible to nominate candidates to Edogawa NICHE Prize (www.edogawanicheprize.org). The Joyce and James Till Travel Grant (www.j2t2grant.org) instituted in 2018, with a grant by Prof. James Till, 2018 Edogawa NICHE Prize recipient, was awarded this year to Dr. Rupesh Kumar Natarajan, (2013 FCQ elite), now pursuing fellowship in pediatric cardiology, University of Minnesota, USA.

FCQ as an innovation platform, has started attracting multinational companies for collaboration following development of novel solutions like BEES-HAUS for urethral stricture (https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852), cartilage repair (https://www.sciencedirect.com/science/article/pii/S2352320420300274) and the recently granted patent on microgravity based enhancement of nitric oxide synthesis by blood cells, specially NK cells.

Dr. Shojiro Katoh, (Founder, EELS) congratulated the winners and hopes to invite to Japan beside honoring the 2020 Edogawa NICHE Prize recipient Dr. John Venter in the coming years, by when the Boron Neutron Capture Therapy (BNCT) in Edogawa Hospital (http://bnct-cancer.com/center.php) could be ready to offer treatment to cancer patients from abroad and start research collaboration with overseas institutes. Event information will be updated in: www.ncrmniche.org

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Samuel JK Abraham
info@gncorporation.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dream Accelerates Growth of Asset Management Platform With Acquisition of Chancerygate, a Leading U.K.-Based Industrial Asset Manager and Developer31.7.2026 01:09:00 EEST | Press release

Dream Unlimited Corp. (“Dream”) (TSX: DRM) today announced that Dream and Dream Industrial Real Estate Investment Trust (“Dream Industrial REIT”) (TSX: DIR.UN), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. Chancerygate currently manages a diversified portfolio of income producing and development assets totaling £1.2 billion ($2.2 billion). As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chancerygate's wholly owned real estate assets and co-investment interests across its managed ventures for consideration of approximately £78 million ($147 million), gross of certain in-place debt, and expects to fund an additional £25 million ($47 million) to complete the wholly owned development projects. The transactions a

Dream Industrial REIT Announces Entry Into U.K. Multi-Let Industrial Market and Growth of Strategic Private Ventures in Europe31.7.2026 01:06:00 EEST | Press release

Dream Industrial Real Estate Investment Trust (TSX: DIR.UN) (the “Trust” or the “REIT” or “DIR”) today announced that the Trust and Dream Unlimited Corp. (TSX: DRM) (“Dream”), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730297448/en/ Audio Park, Sussex, UK - 104,000 sq ft As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chancerygate's wholly owned real estate assets and co-investment interests across its managed ventures for consideration of approximately £78 million ($147 million), gross of certain in-place debt on the wholly owned real estate assets, and expects to fund an additional £25 million

Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results30.7.2026 23:03:00 EEST | Press release

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730702735/en/ Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results “Second-quarter results and four consecutive quarters of improved growth metrics demonstrate strong demand for our core Rimini Support™ offering, increasing adoption of our broader enterprise software services portfolio and improving sales execution,” said Seth Ravin, president and CEO, Rimini Street. “Real innovation is not about installing a software vendor’s next ‘.ai’ release — it is about reducing total operating costs, improving profitability and enhancing competitive

Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service30.7.2026 23:01:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of Rimini Govern™ for AI, the newest offering in the company’s Rimini Govern portfolio of Governance, Risk and Compliance (GRC) solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730389723/en/ Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service The new managed service is delivered 24/7/365 through Rimini Street’s Global Command Centers by expert AI engineers to help organizations: Accelerate AI agent deployment Reduce AI agent operational risk Increase visibility into AI agent activity Provide AI agent activity audit capability Control AI agent operating costs Measure business value from AI agent investments Scale AI agent adoptio

One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples30.7.2026 22:03:00 EEST | Press release

One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded (FFPE) pathology specimens obtained in routine cancer care using the company’s proprietary platform, OneMap™. The study, conducted with collaborators at Centre Léon Bérard, Hôpital Bichat–Claude Bernard, Institut Curie, and Memorial Sloan Kettering Cancer Center, was released as a preprint on BiorXiv. “Every tumor is a unique ecosystem of many different types of cells, some cancerous, some not. Single cell profiling enables us to understand what those cells are, what they’re doing and potentially how that may impact treatment outcomes,” said Helena Yu, MD, thoracic medical oncologist at Memorial Sloan Kettering Cancer Center. “Until now that type of analysis required different types of samples and workflows than we deploy in clinical care. This study shows

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye